Sai Parenterals Q1 FY27 revenue rises sharply to Rs 182.4 crore
Hyderabad, Aug 12(TNT): Sai Parenterals Ltd on Tuesday reported consolidated revenue of Rs 182.4 crore for the first quarter ended June 30, 2026, while EBITDA stood at Rs 27.3 crore and profit after tax at Rs 7.9 crore.
In a release, the Hyderabad based integrated pharmaceutical company said gross profit stood at Rs 76.2 crore, with gross margin improving to 41.8 per cent from 38.1 per cent in the previous quarter.
EBITDA margin stood at 14.9 per cent, compared with 14.4 per cent in Q4 FY26.
The company said Q1 FY27 revenue represented around 24 per cent of its full-year revenue target of Rs 750 crore and was ahead of the phasing implied by its guided 45:55 split between the first and second halves of the financial year.
It cautioned that the year-on-year consolidated comparison was not like-for-like as Q1 FY27 included a full quarter of Noumed Pharmaceuticals, which was consolidated only from November 12, 2025.
On a standalone basis, revenue rose 174.8 per cent year-on-year to Rs 56.2 crore from Rs 20.4 crore in Q1 FY26. EBITDA increased 292.7 per cent to Rs 16.8 crore, while profit after tax surged 975.1 per cent to Rs 8.9 crore.
The Board has approved a proposal to redeploy Rs 101.85 crore of IPO proceeds, comprising Rs 83.83 crore earmarked for manufacturing capacity expansion and Rs 18.02 crore for a new research and development centre, towards acquiring majority stakes in two pharmaceutical assets.
The proposal is subject to shareholders’ approval.
Under the proposed restructuring, the company plans to acquire a 60 per cent stake in Saicriti Pharma Pvt Ltd for Rs 83.83 crore.
Saicriti is developing a Rs 215-crore critical-care injectable facility at Gummadidala, near Hyderabad, with capacity for complex injectables, lyophilisation and GLP-compliant laboratories. The facility is being built to EU-GMP and USFDA standards.
The proposed facility is expected to provide around 154.66 million units of injectable capacity, about 47 per cent higher than the 105 million units planned under the original expansion proposal, with completion now targeted for April 2027.
The company’s research subsidiary, SP Analytics Pvt Ltd, also proposes to acquire a 60 per cent stake in Prathyak Laboratories Pvt Ltd for Rs 18.02 crore.
Prathyak operates an established R&D centre at Genome Valley, Hyderabad, with 65 personnel, including 28 research scientists, and a pipeline of 150 SKUs across 86 molecules.
In Australia, Sai Parenterals said funding for its AUD 53-million programme has been completed. Construction is on schedule, with physical completion targeted for January 2027, TGA licensing inspection expected by March 2027 and Phase 1 manufacturing scheduled to begin in April 2027.
The Board has also approved the incorporation of a US subsidiary to evaluate entry into the American market. The company said the evaluation is at a preliminary stage.
Chairman and Managing Director Anil Kumar Karusala said the company was running ahead of the pace required to meet its FY27 guidance and reiterated the revenue target of Rs 750 crore at an EBITDA margin of around 17 per cent.
He said pricing benefits were continuing to flow through, while deferred volumes were expected to be recovered in the second half of the financial year.
TNT TS
